Delivery Order SPE2DB24D1007-SPE2DB25FCCVD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Jatenzo 237 mg capsules (120 count) with a ceiling value of $2,263.74. This is a firm fixed-price contract with an ultimate completion date of September 18, 2025. The award was competitively made with no set-aside designation, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a...
- The Defense Logistics Agency awarded a delivery order valued at $1,256.92 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 158 mg on July 14, 2025, with completion scheduled for July 15, 2025. This firm fixed-price, competitively awarded contract represents a small-value pharmaceutical delivery with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Jatenzo 237 mg capsules (120 count) valued at $1,640.34. This firm fixed-price delivery order, which is scheduled for completion by August 27, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation. AmerisourceBergen,...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $1,636.67. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency has awarded AmerisourceBergen Drug Corp a delivery order valued at $3,347.66 for Jatenzo 198 mg capsules (120-count units) with a completion date of September 4, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is listed as Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,988.39 to AmerisourceBergen Drug Corp for 120 capsules of Jatenzo 237 mg on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Jatenzo 237 mg capsules (120 count) at a ceiling value of $2,263.74. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The ultimate completion date is set for August 19, 2025, with performance originating from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jatenzo 237 mg capsules (120-count units) with a ceiling value of $2,263.74. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a $8,442.15 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Jatenzo 237 mg capsules (120-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 24, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jatenzo 237 mg capsules (120 count) under a firm fixed-price contract with a ceiling value of $1,131.87. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery...
- SPE2DB24D1007Indefinite Delivery Contract
- SPE2DB24D1007-SPE2DB25FCCVDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jatenzo 198 mg capsules (120-count units) valued at $1,131.88 under a firm fixed-price contract. This is a non-set-aside competitive award with an ultimate completion date of August 13, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products across multiple therapeutic domains on a competitive basis. This specific delivery order for Jatenzo, a testosterone replacement therapy medication, exemplifies the company's role in fulfilling specialized pharmaceutical needs for the Defense Health Agency and other government healthcare programs through the DLA's flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/12/25 |